Sign in Create account

Marksans Pharma Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: MARKSANS BSE: 524404
₹322.30
▼ -20.45 (-5.97%)
Sept. 30, 2026 · NSE · nse_bhavcopy
Quality
69/100
Moderate
Valuation
12/100
Expensive
Momentum
50/100
Neutral

QVM read Mixed signals Quality Moderate, Valuation Expensive, Momentum Neutral

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹14,605 Cr
PE (TTM)
45.5
Industry median 36.1 (152 companies)
Price to Book
4.8
PEG (TTM)
Data unavailable (needs 8 quarters of EPS).
Institutions holding %
23.66%
FII + DII, latest filed period
Piotroski Score
7
Relative return vs Nifty50, qtr %
38.0
Relative return vs Sector, qtr %
19.9
Free Cash Flow
₹328 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
43.40%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
61.86%
as of June 30, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
12.40%
as of June 30, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
43.66%
as of June 30, 2026
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
0.45%
as of June 30, 2026
Industry median 14.05% (173 companies)
Current Ratio
5.17
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
0.01
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
307.54
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
21.49%
as of June 30, 2026
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
28.27%
as of June 30, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
31.26%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
10.88%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
17.54%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
13.76%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

5 of 8 met
  • No Net profit is higher than a year earlier in each of the last 4 quarters
  • Yes Revenue is higher than a year earlier in each of the last 4 quarters
  • No Quality score is Strong (70 or more)
  • Yes Piotroski F-score is 7 or more (score 7)
  • Yes Debt to equity is below 0.5 (0.01)
  • No Return on equity is 15% or more (13.8%)
  • Yes Net cash flow for the latest year is positive
  • Yes Cash from operations is higher than the year before

Ownership

3 of 3 met
  • Yes FII/FPI or DII holding rose in the latest quarter
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)

Peer comparison

2 of 3 met
  • Yes 1-year return beats the industry median
  • No Revenue growth beats the industry median
  • Yes Profit growth beats the industry median

Value and momentum

1 of 6 met
  • No Price sits in the Buy zone of its own historical PE range (Fair Value Zone)
  • No Valuation score is Undervalued (70 or more)
  • No Momentum score is Bullish (70 or more)
  • No Price is above the 5, 10 and 20 day averages
  • Yes Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs NIFTY 50)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
-6.0%
Low 321.0000 · High 345.9000
1W return
-7.3%
Low 321.0000 · High 350.9500
1M return
0.2%
Low 301.1000 · High 350.9500
52W return
93.4%
Low 155.0000 · High 350.9500
Lifetime High ₹353.4000 (Dec. 2, 2024)
Lifetime Low ₹1.3500 (June 21, 2012)

Full price history and technicals →

Technicals

Full technicals, indicators & Volume/Delivery →

EMA & SMA

Bullish3
Bearish3
5D
332.3
10D
332.3
20D
328.8
50D
310.6
100D
281.8
200D
227.3

Delivery and volume

Day avg. delivery
39.4%
Week avg. delivery
35.5%
Month avg. delivery
37.0%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

329.73
Pivot
First resistance338.47
Second resistance354.63
Third resistance363.37
First support313.57
Second support304.83
Third support288.67
Day RSI48.6
Day MFI53.9
Day MACD6.12
Day MACD signal7.57

Beta

1M2.37
3M0.80
1Y1.03
3Y1.13

Price change analysis

↑ 0.2%
Over 1 Month
LowHigh
301.10350.95
↑ 19.9%
Over 3 Months
LowHigh
239.65350.95
↑ 91.8%
Over 6 Months
LowHigh
160.60350.95
↑ 93.4%
Over 1 Year
LowHigh
155.00350.95
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 45.5 (own history: 23.7–87.9)
Fair Value Zone

Financials

View full financials, peers & valuation multiples →
Revenue (June 30, 2026)
₹321 Cr
Net profit (June 30, 2026)
₹69 Cr
Basic EPS (June 30, 2026)
₹1.5200

Ranks #39 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter43.87%
  • Mutual funds4.36%
  • FII/FPI17.47%
  • Other DII1.83%
  • Public32.47%

Largest holders

NameCategoryShares %Shares
MARK SALDANHAPromoter43.8000%198491553
ORBIMED ASIA IV MAURITIUS FVCI LIMITEDPublic8.6200%39050881
UTI-HEALTHCARE FUNDPublic2.1100%9561028
KOTAK MAHINDRA TRUSTEE CO LTD A/C KOTAK SPECIAL OPPORTUNITIES FUNDPublic1.1400%5147937
SANDRA SALDANHAPromoter0.0700%330456

As of June 30, 2026. Only holders the filing discloses individually.

Historical promoter holding

Promoters holdings were unchanged at 43.87% in Jun 2026 qtr

Historical fii holding

FII/FPI holdings increased from 16.76% to 17.47% in Jun 2026 qtr

Historical mutual fund holding

Mutual funds holdings decreased from 4.66% to 4.36% in Jun 2026 qtr

2 mutual fund schemes also hold this stock.

All shareholding details →

Insider trading, SAST & pledges

All 18 insider trades, 5 SAST, 0 pledge events →

Latest insider trades

FiledPersonCategoryTypeQuantityValue
6 Jun 2024 Sandra Saldanha Other Buy 0 ₹0
4 Jun 2024 Sandra Saldanha Other Buy 0 ₹0
22 Aug 2023 Arvind Singh Other Sell 0 ₹0
22 Aug 2023 Arvind Singh Other Sell 0 ₹0
22 Aug 2023 Arvind Singh Other Buy 0 ₹0
22 Aug 2023 Arvind Singh Other Sell 0 ₹0
22 Aug 2023 Arvind Singh Other Sell 0 ₹0
22 Aug 2023 Arvind Singh Other Sell 0 ₹0
22 Aug 2023 Arvind Singh Other Buy 0 ₹0
22 Aug 2023 Arvind Singh Other Sell 0 ₹0

All insider and SAST disclosures →

Deals (Bulk & Block)

All 96 deals, with filters and CSV →
DateClientDealActionQuantityPriceExchange
12 Aug 2026 MICROCURVES TRADING PRIVATE LIMITED Bulk Sell 4,349,697 313.4000 NSE
12 Aug 2026 MICROCURVES TRADING PRIVATE LIMITED Bulk Buy 4,349,697 313.2400 NSE
28 Jul 2025 UNIFI CAPITAL PRIVATE LIMITED Bulk Buy 7,241,309 231.5000 BSE
11 Jun 2025 UTI MUTUAL FUND Block Buy 414,093 249.9500 NSE
11 Jun 2025 UNIFI CAPITAL PRIVATE LIMITED -BLENDED RANGOLI Block Buy 3,247,600 249.9500 NSE
11 Jun 2025 UNIFI CAPITAL PRIVATE LIMITED Block Buy 594,000 249.9500 NSE
11 Jun 2025 UNIFI BLEND FUND 2 Block Buy 3,000,000 249.9500 NSE
11 Jun 2025 UNIFI BCAD FUND Block Buy 560,000 249.9500 NSE
11 Jun 2025 SUBHKAM VENTURES I PRIVATE LIMITED Block Buy 537,485 249.9500 NSE
11 Jun 2025 SOCIETE GENERALE Block Buy 920,184 249.9500 NSE

All bulk and block deals →

Dividends

Full dividend history →
Last 12 months ₹0.90 per share
Dividend yield 0.28%
Ex-dateSubjectPer share (₹)Record date
— Final Dividend - Rs. - 0.9000 — —
20 Aug 2026 Dividend - Re 0.90 Per Share 0.9000 20 Aug 2026
1 Aug 2025 Dividend - Re 0.80 Per Share 0.8000 1 Aug 2025
17 Sep 2024 Dividend - Rs 0.60 Per Share 0.6000 17 Sep 2024
7 Jun 2023 Dividend - Re 0.50 Per Share 0.5000 7 Jun 2023
19 Aug 2022 Annual General Meeting/Dividend - Rs 0.25 Per Share 0.2500 —
15 Sep 2021 Annual General Meeting/Dividend - Rs 0.25 Per Share 0.2500 —
22 Sep 2020 Annual General Meeting/Dividend - Rs 0.10 Per Share 0.1000 —
19 Sep 2019 Annual General Meeting/Dividend - Rs 0.05 Per Share 0.0500 —
19 Sep 2018 Annual General Meeting/Dividend Re 0.05 Per Share 0.0500 —

Corporate Actions

Full history (25 events) →

Bonuses, splits, buybacks and other events. Dividends are listed separately above.

Ex-dateTypeSubject
11 Mar 2008SPLITFv Split Rs.10/- To Re.1/
1 Jul 2021OTHER Extra-Ordinary General Meeting
19 Sep 2013OTHERAnnual General Meeting
20 Sep 2012OTHERAnnual General Meeting
22 Sep 2011OTHERAnnual General Meeting
22 Sep 2010OTHERAnnual General Meeting

All corporate actions →

Board Meetings

View board meeting history →

Quarterly results, AGMs, buybacks and other board-approved business.

DatePurposeResults
12 Aug 2026 Financial Results Yes
26 May 2026 Financial Results/Dividend Yes
5 Feb 2026 Financial Results Yes
13 Nov 2025 Financial Results Yes
12 Aug 2025 Financial Results Yes

Corporate Announcements

All 736 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
25 Sep 2026 Trading Window Marksans Pharma Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
25 Sep 2026 Insider Trading / SAST Marksans Pharma Ltd - 524404 - Closure of Trading Window
17 Sep 2026 General Updates Marksans Pharma Limited has informed the Exchange regarding opening of Special Window for Re-lodgment of Transfer Requests of Physical Shares
7 Sep 2026 Copy of Newspaper Publication Marksans Pharma Limited has informed the Exchange about Copy of Newspaper Publication regarding transfer of unclaimed dividend and equity shares of the Company to the IEPF
1 Sep 2026 Analysts/Institutional Investor Meet/Con. Call Updates Marksans Pharma Limited has informed the Exchange about Schedule of Investors Meet
27 Aug 2026 Shareholders meeting Marksans Pharma Limited has submitted the Exchange a copy Srutinizers report along with voting result of Annual General Meeting held on August 27, 2026.
27 Aug 2026 Shareholders meeting Marksans Pharma Limited has informed the Exchange regarding Proceedings of 34th Annual General Meeting held on August 27, 2026
26 Aug 2026 General Updates Intimation Under Regulation 30 The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 ESG score by Crisil ESG Ratings & Analytics Ltd
20 Aug 2026 Analysts/Institutional Investor Meet/Con. Call Updates Marksans Pharma Limited has informed the Exchange about Transcript of Investors/Analyst meet Q1 FY 27 Financial Results
13 Aug 2026 Analysts/Institutional Investor Meet/Con. Call Updates Marksans Pharma Limited has informed the Exchange about Link of Recording of Conference call Q1 FY 27 Financial Results

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Strong net profit margin (21.5%)
  • Low financial leverage (Debt/Equity 0.01)
  • Comfortable interest coverage (307.5x)

Weaknesses

Data unavailable.

Opportunities

Data unavailable.

Threats

  • PE above 35 (45.5) -- priced for continued strong execution

Board of directors and corporate information →

F&O

View F&O, Options & Backtest →

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Marksans Pharma Limited

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.